报名：首届全球心血管大会 | 最新议程 GA Monitor 合作伙伴征集：2025全球手术机器人大会 近日，拓普康集团（Topcon Corporation）旗下企业—— 拓普康医疗（Topcon Healthcare） 宣布 收 购 RetInSight ，后者以 视网膜成像 AI 解决方案 的创新研发著称。 基于 AI 的先进方法应用于 OCT 数 据 可以实现视网膜病理的检测和量化，有助于提高多种视网膜血管疾病诊断的准确性，并能够进一步形 成新的诊断标准。 此次收购进一步推动了拓普康医疗"从眼开始的医疗"（Healthcare from the Eye™）愿景，通过智能诊 断技术提升优质眼科护理的可及性，降低医疗成本并优化临床效果。 RetInSight 成立于2020年，是一家奥地利私营企业，致力于开发先进的 变革性 AI 软件 ，利用AI算法提 升视网膜疾病的早期诊断能力。RetInSight 平台已经在欧洲广泛商业化，并且具有供应商包容性， 支持 与各种OCT系统的互操作性 。 凭借其AI驱动的OCT图像分析技术，RetInSight 平台 能够覆盖四种常见 的致盲性眼疾 。 拓普康医疗 作为O ...

报名：首届全球心血管大会 | 最新议程 合作伙伴征集：2025全球手术机器人大会 2025年5月7日，西门子医疗公布2025年第二季度财报以及2025年上半年财报。 第二季度收入达到约 59亿欧元 ， 增长了6.8%。 | Siemens Healthineers | Q2 | Q2 | | % Change | | --- | --- | --- | --- | --- | | (in millions of €) | 2025 | 2024 | Act. | Comp.1 | | Revenue | 5,909 | 5,435 | 8.7% | 6.8% | | Adjusted EBIT2 | 982 | 822 | 19% | | | Adjusted EBIT margin | 16.6% | 15.1% | | | | Net income | 537 | 431 | 25% | | | Adjusted basic earnings per share3 | 0.56 | 0.55 | 3% | | | Basic earnings per share | 0.47 | 0.38 | 24% | ...

Core Viewpoint - The article emphasizes the importance of a comprehensive understanding of the medical and health ecosystem, highlighting the need for entrepreneurs to develop strategic thinking and innovative capabilities to navigate the complexities of the industry [4][11]. Group 1: Program Overview - The program aims to cultivate leadership talents in the medical and health sector by providing a robust academic support system, innovative platforms, and clinical transformation resources [6][9]. - It features a unique value engine methodology that focuses on collaborative efforts between academia and industry to enhance strategic vision and innovation capabilities [7][8]. Group 2: Course Benefits - The curriculum addresses trends, challenges, and innovations in the medical industry, helping participants understand the development trajectory and future direction of the sector [11]. - It explores how to create a sustainable growth strategy in uncertain environments, emphasizing the importance of opportunity identification and risk avoidance [12][13]. Group 3: Curriculum Modules - The program includes modules on entrepreneurial thinking in uncertain times, macroeconomic growth logic, and strategic diagnosis for effective execution [16]. - It covers value discovery and business model design, focusing on identifying unique values in the medical and health sector [16]. Group 4: Industry Insights - The curriculum discusses the integration of technology in healthcare, including the analysis of consumer medical segments and the application of AI, big data, and cloud computing [17]. - It also examines the silver economy, exploring opportunities and challenges in sectors like elderly care, healthcare, and rehabilitation [16]. Group 5: Networking and Resources - The program facilitates connections with top-tier resources, including visits to leading hospitals and enterprises in the medical field, fostering collaboration and innovation [21]. - It offers global learning opportunities, including visits to prestigious institutions in the U.S. and Europe, enhancing the participants' exposure to international best practices [20][21].

报名：首届全球心血管大会 | 最新议程 合作伙伴征集：2025全球手术机器人大会 2025年4月27日，NMPA公布了创新医疗器械特别审查申请审查结果公示（2025年第4号），有 9款产品 进入创新通道。其中包括， 杭州德适生物科技有限公司 申请的 染色体核型辅助诊断软件 。 德适生物的 染色体核型 辅助诊断设备 ，由 MetaSight ® 自动细胞显微图像扫描系统 和 AutoVision ® 智能染色体核型分析系统 组成，突破了染色体核型智能高速 扫描与智能辅助分析的难题，实现了智能高效染色体核型辅助分析，可以快速精准辅助诊断数千种染色体异常，染色体核型分析临床报告出具时间缩短 至 4-7天 ， 人耗降低为传统的 七分之一至十分之一 。目前 该产品已经获得 中国NMPA注册证、欧盟CE认证和美国FDA注册证 。 # 研发背景 染色体核型检测 是一种重要的遗传学检查方法，它通过分析染色体的数目、结构、形态以及是否存在基因突变等，来评估个体的遗传物质状态。这项检测对于优生优 育、遗传病诊断以及生殖健康等方面具有重要意义。染色体异常是导致出生缺陷遗传学病因的重要组成部分，可能引起不孕、不育、反复流产、死胎、生 ...

报名：首届全球心血管大会 | 最新议程 合作伙伴征集：2025全球手术机器人大会 近日， 凯利泰 发布了2024年年报和2025年一季报。 | | 2024 年 | | 2023 年 | | 本年比上年增减 | 2022 年 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 营业收入(元) | 984,518,762.54 | | 956,259,537.45 | | 2.96% | 1,166,042,082.06 | | | 归属于上市公司股东的净利 | -105,565,367.23 | | 112,537,303.89 | | -193.80% | -21,282,494.18 | | | 润(元) | | | | | | | | | 归属于上市公司股东的扣除 非经常性损益的净利润 | -65,305,422.66 | | 61,648,763.58 | | -205.93% | -27,098,445.37 | | | (元) | | | | | | | | | 经营活动产生的现金流量净 | 157,752,381.96 | | 274, ...

报名：首届全球心血管大会 | 最新议程 合作伙伴征集：2025全球手术机器人大会 2025年5月7日，波士顿科学（纽约证券交易所代码：BSX）宣布， 完成对 血管内超声系统开发商 SoniVie的收购。 此次收购使波士顿科学正式进入竞争激烈的肾动脉去神经术（Renal Denervation, RDN）领域。 # 收购详情 波士顿科学此前已是SoniVie的战略投资者，持有其约 10%的股权 。此次交易中，波士顿科学为收购尚 未持有的 90%股权支付了约 3.6亿美元 的预付款 。 此外，交易还包括最高达 1.8亿美元 的潜在监管里程碑付款 。不考虑股权因素，波士顿科学将此次交易 估值为4亿美元预付款加上2亿美元里程碑付款， 总计6亿美元 （约合43亿人民币）。 波士顿科学全球副总裁及心脏介入事业部总裁Lance Bates 表示，"经肾动脉去交感神经术治疗高血压是 一项激动人心的医学进步，有望造福数百万患者。这一疗法已在当前临床试验与持续开展的研究中收获了 积极成果。 我们相信，TIVUS 系统能为我们丰富的介入产品组合增添针对高血压患者的微创疗法，为这 一领域的未来发展提供更多可能。 " # TIVUS血 ...

Core Viewpoint - The article discusses the financial performance of Chenguang Medical in 2024, highlighting significant declines in revenue and net profit compared to previous years, indicating potential challenges for the company moving forward [2][3]. Financial Performance - In 2024, the company achieved operating revenue of 119 million, a decrease of 28.16% compared to 2023 [2][3]. - The net profit attributable to shareholders was -60.89 million, reflecting a decline of 416.85% year-on-year [2][3]. - The net profit after deducting non-recurring gains and losses was -68.39 million, down 268.45% from the previous year [2][3]. - The gross profit margin improved to 38.24% from 35.01% in the previous year [2]. - The basic earnings per share were -0.71, a significant drop of 407.14% compared to -0.14 in 2023 [2]. Cash Flow and Expenses - The net cash flow from operating activities was -28.48 million, a decrease of 82.06% year-on-year [8]. - Total expenses for the year were 90.94 million, an increase of 2.11 million compared to the previous year, with an expense ratio of 76.42%, up 34.25 percentage points [8]. Business Overview - Chenguang Medical focuses on the research, development, production, and sales of MRI systems and their core components, including superconducting magnets and RF detectors [6][7]. - The company aims to drive business growth through technological innovation and market expansion, optimizing its product line and enhancing market competitiveness [9]. - In 2024, the company expanded its operations to include internet information services for medical devices and various medical device production and management [9].

Core Viewpoint - The company, Jiangsu Lude Medical Electronics Co., Ltd., reported a revenue increase of 4.66% in 2024, but experienced a decline in net profit by 13.08%, indicating challenges in profitability despite revenue growth [1][2]. Financial Performance - The company achieved operating revenue of 344.60 million in 2024, up from 329.26 million in 2023, reflecting a growth of 4.66% [1][2]. - The net profit attributable to shareholders was 27.54 million, down 13.08% from 31.69 million in the previous year [1][2]. - The net profit after deducting non-recurring gains and losses was 26.21 million, a decrease of 12.64% compared to 30.00 million in 2023 [1][2]. - The weighted average return on equity based on net profit attributable to shareholders was 7.00%, down from 8.19% in 2023 [1]. - Basic earnings per share decreased to 0.16 from 0.18, reflecting a decline of 13.08% [1]. Business Overview - Jiangsu Lude Medical focuses on the research, development, production, and sales of home medical devices and healthcare products [5]. - The company has been listed on the Beijing Stock Exchange since November 15, 2021, after being one of the first 32 companies to go public on the selected tier [5]. - The main product categories include home medical devices such as blood pressure monitors, nebulizers, and thermometers, as well as healthcare products related to family health management [6]. Cash Flow and Assets - The net cash flow from operating activities was 13.03 million, showing a significant decline of 61.70% year-on-year [5]. - As of the end of 2024, total assets amounted to 530 million, an increase of 7.94% compared to the previous year [5]. - The equity attributable to shareholders was 400 million, reflecting a growth of 2.61% [5]. Research and Development - The company continued to invest in research and development, with R&D expenses increasing by 4.33% in 2024, aimed at product innovation and technological upgrades [5]. Market Expansion - The company actively expanded its overseas market presence, achieving significant sales growth through cross-border e-commerce platforms [5]. - In 2024, several products received EU MDR CE certification and MDSAP certification, enhancing competitiveness in international markets [5].

报名：首届全球心血管大会 | 最新议程 合作伙伴征集：2025全球手术机器人大会 2025年5月6日，飞利浦公布了2025年第一季度最新财报。此前公司表示，美国与中国（以及其他国家和 地区）之间的关税将对今年的业绩产生 2.5亿至3亿欧元的影响。 飞利浦在财报中 维持了其可比销售额增长1%至3%的预期，但将其全年调整后的EBITDA利润率预期从 11.8%至12.3%下调至 10.8%至11.3%。 # 财 报亮点 # 业务详情 | | Q1 2024 | Q1 2025 | | --- | --- | --- | | Sales | 2,026 | 1,965 | | Nominal sales growth | 1% | (3%) | | Comparable sales growth 1 | 3% | (4%) | | Income from operations | 146 | 153 | | as a % of sales | 7.2% | 7.8% | | EBITA 1 | 168 | 173 | | as a % of sales | 8.3% | 8.8% | | Adjusted EBIT ...

Evoke的首席执行官兼首席科学官David Hagedorn博士表示，"Evoke和Firefly之间可以产生商业协同效 应，我们将携手合作，建立一个强大且不断发展的业务。" Firefly Neuroscience 的首席执行官Greg Lipschitz说，" BNA ™ 数据库在每一次新的 临床研究和/或临床评估中不断扩展，我们相信收购Evoke是 Firefly Neuroscience实现其目标的关键一 步， 建立世界上第一个基于EEG/ERP的人类大脑基础模型 。" # 3天上涨近400% 报名：首届全球心血管大会 | 最新议程 合作伙伴征集：2025全球手术机器人大会 2025年5月5日， Firefly Neuroscience （纳斯达克股票代码：AIFF）宣布收购 Evoke Neuroscience ，后者是一家创新医疗器械公司，主要开发和商业化用于辅助全面评估大脑健康的技术。此次交易标志着 Firefly Neuroscience朝着利用脑网络分析（ BNA ™ ） 技术构建专有的人脑基础模型迈出了重要一步。 # 收购详情 收购条款包括 支付 600万美元 （约合人民币 4336万） ...